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Combined endovenous laser therapy and
microphlebectomy in the treatment of varicose
veins: Efficacy and complications of a large
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Carlos F. Fernández, MD, Moisés Roizental, MD, and Josefina Carvallo, MD, Caracas, Venezuela
Objective: This study evaluated the safety and clinical and anatomic effectiveness of endovenous laser therapy (EVLT) and
microphlebectomy in the treatment of varicose veins secondary to saphenous reflux.
Methods: From January 1, 2005, to December 31, 2007, 1985 EVLT procedures were performed in 1559 eligible patients
(1263 women) with a mean age of 52.8 years (range, 18-89 years). A 810-nm diode laser and microphlebectomy were
used. All sites of superficial axial reflux above and below the knee were ablated. Symptoms of venous insufficiency were
present in 97%, and 102 patients (6.54%) had an open ulcer when they underwent operation. Patients had clinical
follow-up visits, including duplex ultrasound examination, at 1 week, 1 month, 3 months, and yearly and were assessed
for deep venous thrombosis (DVT), recanalization of the ablated vein, nerve injury, ulcer healing, and resolution of
symptoms.
Results: A total of 1652 great saphenous veins (83.22%), 285 small saphenous veins (14.36%), 40 anterolateral tributaries
(2.02%), and 8 posteromedial tributaries (0.40%) were ablated. An average of 19 phlebectomies were performed per case
treated (range, 1-58). The primary ablation rate at 15 and 30 months was 91.26% and 78.25% by Kaplan-Meier analysis.
Recanalization occurred in 35 veins (1.76%); in this group, 15 (42.9%) exhibited symptoms of venous insufficiency and
were successfully closed with a second EVLT. Body mass index >30 kg/m2 and a vein diameter >8.5 mm were the only
factors predictive of recanalization. Postoperatively, the 102 ulcers showed healing at a mean of 5.2 weeks (range, 2-10
weeks), and only three reopened (2.94%). No major complications occurred. Two DVT (0.13%) occurred, but no
pulmonary emboli or skin burns. Local transient paresthesia at the ankle and midcalf level occurred in 38 patients
(2.43%).
Conclusions: EVLT of all sites of superficial axial reflux above and below the knee and microphlebectomy demonstrated
that the combined approach is safe and effective at eliminating reflux, affording symptomatic relief, and healing ulcers. It
offers the additional advantage of resolving varicose veins and its cause in just one visit, leading to immediate better
cosmetic results. ( J Vasc Surg 2008;48:947-52.)Venous insufficiency is a genetically influenced, chronic,
and progressive disorder. The ultimate goal of any treat-
ment regimen is to eliminate sources of reflux in order to
control symptoms and progression of disease, improve
cosmesis, promote ulcer healing, and prevent recurrence or
a combination of these. The best therapeutic results are
based on two hemodynamic principles: the abolishment of
the highest point of reflux and the elimination of the
incompetent and dilated venous segments.
Endovenous laser treatment (EVLT) allows delivery of
laser energy directly into the vein lumen. Published reports
confirm that endovenous laser ablation of an incompetent
great saphenous vein (GSV)1-6 or small saphenous vein
(SSV)7,8 is safe9 and can provide outcomes equal to or
better than traditional surgical ligation and stripping.10-13
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doi:10.1016/j.jvs.2008.05.029Some practitioners advocate ablating the thigh seg-
ment of the GSV and treating the remaining visible varicos-
ities with sclerotherapy during subsequent follow-up visits.
Our chosen protocol is to perform EVLT of all refluxing
truncal veins, above and below the knee, and to remove all
varicose veins with microphlebectomies (MPs) at the same
time. This approach mirrors past protocols in which the
incompetent GSV was stripped in combination with stab
avulsion of varicosities. Several large series have included
GSV, SSV, anterolateral tributary (ALT) and posterome-
dial tributary (PMT) EVLT ablations, but studies specifi-
cally of the success rate and risks associated with EVLT
combined with MP have included only a small number of
patients.14,15 The purpose of this study is to report the
safety and clinical and anatomic effectiveness of the com-
bined application of EVLT and MP in a large number of
patients from a single center.
MATERIALS AND METHODS
Patient selection and criteria. This prospective co-
hort observational study included 1559 patients with ve-
nous insufficiency who presented for routine evaluation at
the vein clinic and underwent 1985 EVLT ablations. Di-
rected history and physical examination was performed to
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CEAP classification. All patients had preoperative docu-
mentation of axial venous reflux using a Sonosite (Sonosite
Inc, Bothell, Wash) duplex ultrasound (DUS) unit.
Inclusion criteria included varicose veins caused by
saphenous reflux (GSV and SSV) and their tributaries in
patients aged 18 years. Exclusion criteria included non-
palpable pedal pulses, inability to ambulate, deep vein
thrombosis (DVT), general poor health; pregnancy, breast-
feeding, or plan to become pregnant immediately after
treatment; and extremely tortuous veins that would not
allow endovenous catheterization. After an initial examina-
tion and consultation, patients who met the selection cri-
teria were offered the choice of surgery or EVLT. Nearly all
patients chose EVLT rather than surgical ligation and strip-
ping. All patients gave informed consent before treatment.
Technique. All patients were treated as an ambulatory
procedure in the angiography suite under local anesthesia
and conscious sedation using intravenous benzodiazepine.
DUS imaging was done with the patient standing. All
refluxing truncal veins were identified and marked in the
skin, and a percutaneous entry point was chosen where
reflux was no longer seen or where the vein became too
small to access for ablation. Patients were placed in the
supine position and turned to the prone position if the SSV
needed to be ablated.
With the use of local anesthesia and sonographic guid-
ance, the vein was punctured using the Seldinger tech-
nique. If we were unable to gain access percutaneously, the
vein was pulled out with a crochet needle at the marked
entry point through a 2-mm skin incision. A 5F introducer
sheath was placed into the vein over a guidewire and
advanced past the saphenofemoral junction (SFJ) into the
common femoral vein in the GSV, ALT, and PMT cases
(Fig 1), and past the saphenopopliteal junction (SPJ) into
the popliteal vein in the SSV cases, accessing at the ankle
level if needed to ablate the entire length of a refluxing vein.
The intraluminal position within the vein was con-
firmed by aspiration of nonpulsatile venous blood and
visualization with ultrasound. A 600-m laser fiber was
introduced into the sheath and advanced to the first site
mark. The sheath was then withdrawn to the second site
mark, exposing the distal 3 cm of the bare-tipped laser fiber.
The sheath and fiber were pulled back together and posi-
tioned at the superficial venous system under ultrasound
guidance. Position was confirmed by direct visualization of
the red aiming beam of the laser fiber through the skin.
Tumescent local anesthesia, consisting of 200 to 400
mL of 0.1% lidocaine neutralized with sodium bicarbonate,
was administered along the perivenous space under ultra-
sound guidance. In addition to its role as an anesthetic,
delivery of diluted lidocaine in the surrounding perivenous
space will (1) compress even the largest diameter veins to
ensure circumferential contact between the laser fiber and
vein walls, maximizing energy transfer, and (2) provide a
fluid barrier protecting adjacent nontarget structures from
heat-related damage.The tip of the laser fiber was repositioned within the
GSV or SSV, 5 to 10 mm distal to the SFJ or SPJ, respec-
tively. Tip position was checked again by ultrasound and
direct visualization of the red aiming beam through the
skin. Laser energy was delivered using an 810-nm diode
laser (Diomed Holdings Inc, Andover, Mass) at 14 W in
continuous mode. The vein was treated from 5 to 10 mm
below the SFJ or SPJ to approximately 1 cm above the skin
entry site. The laser fiber was withdrawn at an average rate
of 1 mm/s for the proximal third of the GSV, the ALT, and
PMT, and 2 mm/s for the rest of the GSV and for EVLT
applied for the SSV and the GSV below the knee. These
rates of withdrawal represent about 140 J/cm and 70 J/cm
of energy delivered, respectively. These steps were repeated
as needed to treat all refluxing truncal veins.
All patients underwent concomitant MP according to
Muller principles described elsewhere.16 An ophthalmic
scalpel was used to make a 2-mm skin incision, and a
crochet device was used to remove the refluxing tributaries
immediately after the laser ablation.
Once the procedure was completed, compression pads
were applied over the treated area, and a low-stretch elastic
compression bandage using Comprilan (BSN Jobst, Inc,
Charlotte, NC) was placed on the treated limb. In the open
Fig 1. Simultaneous access of refluxing veins. Introducer sheath
in the anterolateral tributary (white arrow) and in the great saphe-
nous vein (black arrow).ulcer cases, an Unna boot using Flexidress (Convatec,
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plete healing was achieved.
All patients were encouraged to ambulate the day of the
procedure, to resume their normal daily activities in 2 to 3
days, and to wear the elastic bandage 24 hours a day for 2
days and then to replace it with a 15 to 20 mm Hg,
full-thigh or pantyhose graduated support stocking for at
least 1 month at all times, except to sleep or shower.
Nonsteroidal anti-inflammatory drugs and an oral second-
generation cephalosporin were ordered for the first week
after therapy.
Follow-up protocol. Patients had clinical follow-up
visits, including DUS examination at 1 week, 1 month, 3
months, and yearly thereafter. At the time of the visit,
patients were asked about the severity of immediate post-
procedural pain; timing to resume daily normal activities,
work and exercise; complaints of nerve injury, and about
changes in their extremity symptoms compared with those
before the procedure. The presence of residual varicosities,
edema, skin changes, and ulceration was recorded. The
DUS scans assessed for the presence of DVT and for
saphenous ablation or recanalization, defined as the ab-
sence or presence of flow, respectively, in a previously
ablated vein. At the 3-month visit, patients were asked to
complete a patient satisfaction questionnaire, a nonvali-
dated instrument that we created, asking about relief of
symptoms of chronic venous insufficiency, cosmetic results,
and overall satisfaction.
Statistical analysis. Means and standard deviation
were calculated for continuous variables, t tests were used
to compare continuous variables with normal distribution,
and the Kaplan-Meier survival estimate was used to report
the primary ablation rate. We used this method to link
ablation with mean follow-up, a measure of the strength of
the series, and time after the procedure. Univariate and
multivariate logistic regression was used to quantify the
association of selected risk factors with the incidence of
recanalization of the ablated vein. The risk factors used
were age, gender, preoperative presence of ulcer, weight,
height, body mass index (BMI)30 kg/m2, diameter and
length of the treated vein, and linear endovenous energy
density. The estimated effect of the risk factors is presented
in terms of the odds ratio (OR) and P value. Statistical
significance was set at P .05, and the significant variables
in the univariate model were included in a forward stepwise
fashion for the final multivariate analysis. All calculations
were done with Stata 6.0 software (StataCorp, Collage
Station, Tex).
RESULTS
Three operators performed 1985 endovenous laser ab-
lations in 1559 patients who also underwent MP for treat-
ment of varicose veins during a 36-month period at a single
medical facility. Symptoms were present in 97% of patients,
who had amedian CEAP clinical class of C 3.6 (range, 2-6).
Open ulcers were present in 102 patients (6.54%) at oper-
ation. Demographics and CEAP clinical classification of the
studied population are summarized in Table I.Ablation was performed in 1652 GSVs (83.22%), 285
SSVs (14.36%), 40 ALTs (2.02%) and 8 PMTs (0.4%). Of
the GSVs treated, 49.2% were ablated to the above the knee
level, 28.1% to the knee, 10.8% below the knee, and 1.8% to
the ankle level. Pretreatment vein diameter, measured in
the upright position 1 to 2 cm below the SFJ and SPJ, was
a mean of 9.2 mm (range, 4-26 mm), and a mean of 6.8
mm (range, 4-15 mm) for the GSV and SSV cases, respec-
tively. Vein characteristics of the entire series are reported in
Table II. Patients underwent an average of 19 MPs (range,
1-58).
There were four treatment failures (0.2%). The proce-
dure was a technical failure in two patients because the
cannulation failed in one and the guidewire could not be
passed in the other. The treatment could not be completed
in the two other patients because of a tortuous vein in one
and the laser unit did not function properly in the other.
The primary ablation rate for the 1985 veins treated
during the study period was 91.26% at 15 months and
78.25% at 30 months, as shown by Kaplan-Meier analysis
(Fig 2, Table III). During the study period, 35 veins
recanalized (1.76%) in 35 patients. Of these, symptoms of
venous insufficiency (anatomic and clinical failure) devel-
oped in 15 (42.9%), and they were successfully treated with
a second EVLT. The other 20 patients that showed an open
vein during follow-up were asymptomatic (anatomic fail-
ure), and DUS imaging showed no significant reflux within
a smaller vein; therefore, they did not receive a second
EVLT.
A statistical analysis was performed to ascertain factors
that would increase the risk for recanalization (Table IV).
Patients with a BMI 30 kg/m2 and a vein diameter of
8.5 mm had a statistically significantly greater risk of
recanalization. In the analysis, if 70 J of energy was
delivered per centimeter of ablated vein, the risk of recan-
alization was higher. Among the 15 patients who repre-
Table I. Patient characteristics and disease severity scores
by C category of the CEAP classification
Characteristics No. (%) Means (SD)
Patients 1559
Procedures 1985
Age, years 52.8 (12.6)
Weight, kg 72.4 (15.2)
Height, cm 164 (8.7)
Body mass index 26.5 (4.6)
Sex
Female 1263 (81.01)
Male 296 (18.99)
CEAP
C2 518 (33.2)
C3 263 (16.9)
C4 550 (35.3)
C5 126 (8.1)
C6 102 (6.5)
SD, Standard deviation.sented an anatomic and clinical failure and who underwent
tribut
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had a BMI of 31 kg/m2.
The 102 limbs with an open ulcer that were operated
on showed healing at a mean of 5.2 weeks (range, 2-10
weeks) after the procedure, and only three reopened during
the study period (2.94%). Of the 102 ulcerated limbs,
EVLT of both the GSV and SSV was performed in 38
(37%), and EVLT of the SSV only was performed in 19
(18.6%).
Mild to moderate pain along the course of the treated
vein during the first week and ecchymoses along the area of
tumescent anesthesia administration and at phlebectomy
sites were noted in most patients, as well as indurations.
Superficial phlebitis of associated tributary varicose veins
was noted in 58 patients (2.9%) and resolved with com-
pression therapy and over-the-counter nonsteroidal anti-
inflammatory medication in all cases. Local transient pares-
thesia at the ankle and midcalf level occurred in 38 patients
(2.43%) and resolved spontaneously after 2 weeks. Most of
these patients underwent extensive MP below the knee.
Hyperpigmentation occurred in 62 patients (4%) and cel-
lulitis in 16 (1%). Only two cases (0.13%) of DVT were
found, and both were in the GSV group. One of these
patients, who had May-Thurner syndrome, required en-
dovenous thrombolysis and stent placement at the left
common iliac vein. The second patient had ileofemoral
involvement and was successfully treated after a 6-month
course of oral anticoagulation, with the GSV remaining
Table II. Vein details and laser energy density
Characteristicsa GSV
Veins, No. 1652
Diameter, mm 9.2 (3.5)
Treated length, cm 33.04 (13.7)
Total energy, J 2478 (1043)
Laser energy, J/cm 79.4 (35.4)
GSV, Great saphenous vein; SSV, small saphenous vein; AMT, anterolateral
aContinuous data are presented as means (standard deviation).
Fig 2. Kaplan-Meier analysis shows primary closure rate.occluded. No patients presented with pulmonary embolismor skin burns. Lidocaine toxicity developed in a patient
(0.06%) who required 52 phlebectomies, and this resolved
uneventfully.
Of the 500 patients who completed the patient satis-
faction questionnaire, 93% claimed their symptoms had
diminished to none, 87% were highly satisfied with the
cosmetic results, and 91.4% were willing to undergo the
procedure again.
DISCUSSION
Although GSV reflux is the most common underlying
cause of varicose veins, other sources of superficial reflux
often contribute to or are the sole cause of significant lower
extremity varicosities. For instance, the SSV incompetence
has been associated with the entire spectrum of signs and
symptoms of chronic venous disease, including ulcer-
ation.17 SSV reflux is found in 10% to 20% of patients with
varicose veins, as we did in 14.36% of our studied popula-
tion, and nontrunkal superficial reflux—ALT and PMT—is
identified in 10% to 15% of patients with varicose veins.18
Furthermore, our early experience demonstrated that
EVLT of residual reflux below the knee was required to
control symptoms in a few patients.
The clinical significance of persistent below the knee
(BK) GSV (BK-GSV) reflux after EVLT has been studied
by other investigators. Theivacumar et al19 evaluated 69
limbs after EVLT of the thigh GSV and found BK-GSV
reflux of 1 second duration in 28 (41%). Although the
Aberdeen Varicose Vein Symptom Severity scores im-
proved in this latter group of patients, the change was
significantly less compared with the patients in whom no
reflux was found in the untreated BK-GSV. Those 28
patients also needed more sclerotherapy to complete treat-
ment.19 Similar results have been observed by Timper-
man,20 who also reported that symptomatic relief is ob-
tained safely and effectively with additional EVLT of the
BK-GSV.
Improved understanding of the mechanism of action of
EVLT and its high degree of safety and effectiveness in the
treatment of GSV reflux has led to the exploration of
treatment of non-GSV sources of superficial reflux, with
excellent results.5 Therefore, by targeting all the sources
and length of axial reflux, above and below the knee, we can
provide patients with a safe and superior alternative to
ablating just the proximal portion of a refluxing saphenous
SV ALT PMT
85 40 8
(1.8) 7.9 (2.1) 7.7 (1.6)
(6.7) 11.9 (6.5) 9.3 (3.2)
(515.6) 1105 (634) 947.8 (308)
(34.3) 95.1 (29.5) 104.2 (38.8)
ary; PMT, posteromedial tributary.S
2
6.8
15.8
1224
81.2vein, and this is the rationale behind our approach.
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vantage of resolving the varicose veins in just one visit,
leading to immediate better cosmetic results. Both proce-
dures can be done simultaneously, under local anesthesia
and conscious sedation, without a significant increase of
complications. Our rate of postoperative pain, cellulitis, or
paresthesias is not very different from series where EVLT
was the only procedure performed. None of our patients
found the paresthesias or numbness to be a significant
concern. We did have a smaller number of patients with
postoperative phlebitis compared with those series. This
was not surprising, because leaving bulging saphenous tribu-
taries without an outflow path will likely increase the blood
stasis, with the subsequently increased risk of thrombosis.
Ulcer healing occurred at a mean of 5.2 weeks after
treatment in the 102 patients who underwent the proce-
dure with an open ulcer. Cautionmust be used, however, in
the interpretation of the outcomes of ulcer healing. All
patients underwent concomitant compression therapy
(Unna boot), and this study does not isolate which benefits
came from the EVLT vs the compression therapy. The ulcer
reopened in only three patients, and one of them under-
went a second EVLT due to recanalization of the ablated
vein; the other two patients underwent subfascial endo-
scopic perforator surgery because perforator incompetence
was judged to be the principal reason of ulcer recurrence.
The primary ablation rate for the 1985 veins treated
Table III. Anatomic results during 34 months of follow-u
Follow-up, months Veins at risk, No. Failures, No.
1 1985 5
5 333 10
10 214 10
15 110 4
20 53 4
25 18 1
30 4 1
34 1 0
LFU, Lost to follow-up; CI, confidence interval; SE, standard error.
Table IV. Risk factors for recanalization by univariate
and multivariate analysis
Univariate Multivariate
Variable OR (95% CI) P OR (95% CI) P
Female sex 2.70 .04 1.80 .22
Open ulcer 1.37 .05 1.30 .13
Weight 0.90 .14
Height 1.00 .72
BMI 30 kg/m2 2.37 .05 2.97 .02
Vein diameter
8.5 mm 1.07 .05 1.08 .04
Length of vein 1.00 .90
LEED 70 J/cm 2.32 .05 1.70 .18
BMI, Body mass index; CI, confidence interval; LEED, linear endovenous
energy density; OR, odds ratio.during the years 2005 to 2007 of 91.26% at 15 months and78.25% at 30 months is very similar to published reports.
We only found two studies5,21 reporting the primary abla-
tion rate, by Kaplan-Meier analysis, after EVLT. Almeida
and Raines5 observed a primary closure rate of 92% at 500
days in 819 saphenous veins treated with EVLT, and
Desmyttere et al21 reported a primary ablation rate of 97%
at 4 years in 511 GSVs treated with a 980-nm endovenous
laser. During the study period, 35 veins recanalized
(1.76%), representing an anatomic failure; however, these
veins were noticeably smaller, and 57% of patients were
symptom-free, without recurrent varicose veins. As a pos-
sible explanation, it is likely that shrinking a refluxing vein
to a smaller diameter allowed the valves to completely or
partially close, thus decreasing or eliminating reflux. Only
15 patients (42.9%) in this group presented with symptoms
of venous insufficiency, indicating anatomic and clinical
failure, and they were successfully treated with a second
EVLT. Only one patient, with BMI of 31 kg/m2, pre-
sented with an anatomic failure after his second EVLT,
reflecting the importance of obesity as an independent risk
factor for recanalization.
We observed that a BMI 30 kg/m2 and a vein diam-
eter8.5 mm were independent risk factors for recanaliza-
tion. Timperman22 has also found that obesity was com-
mon among patients in whom recanalization occurred. It is
known that obese patients have increased abdominal and
femoral venous pressure.23 In this latter group of failures, it
is possible that the fibrosis caused by the EVLT was over-
come by increased femoral venous pressure, with the saphe-
nous vein reopening in a proximal to distal fashion, some-
times into a varicose tributary close to the SFJ that
functions similarly to a relief valve. MP of these varicose
tributary at the time of EVLT and ligation of the SFJ to
isolate the GSV from increased venous pressure may im-
prove the success of the endovenous ablation. These find-
ings have relevance in counseling patients before the pro-
cedure about their risk of recanalization and also may
suggest which patients should have a prophylactic ligation
of the saphenous vein to reduce this undesired outcome.
CONCLUSION
The combined approach of EVLT of all sites of super-
ficial axial reflux, above and below the knee, with micro-
phlebectomy was demonstrated to be safe and effective at
, No. Successful treatment, % SE (95% CI)
4 99.40 0.0027 (0.9857-0.9975)
2 97.62 0.0063 (0.9601-0.9859)
2 93.72 0.0136 (0.9045-0.9590)
5 91.26 0.0182 (0.8693-0.9421)
2 87.07 0.0261 (0.8071-0.9145)
0 84.26 0.0380 (0.7507-0.9028)
1 78.25 0.0679 (0.6123-0.8846)
2 78.25 0.0679 (0.6123-0.8846)p
LFU
8
43
9
9
5
3
1eliminating reflux, affording symptomatic relief, and heal-
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varicose veins and their cause in just one visit, leading to
immediate better cosmetic results. Further investigations
may ascertain whether ligating the saphenous vein at the
SFJ or SPJ in patients with vein diameters8.5 mm or with
BMIs 30 kg/m2, will reduce the rate of recanalization,
thus improving the long-term results of EVLT.
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